Lynparza 150 mg Film-Coated Tablets, manufactured by AstraZeneca, is a groundbreaking targeted therapy containing the active ingredient Olaparib. It is a leading PARP inhibitor specifically developed for the treatment of various advanced cancers, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. Lynparza 150 mg is widely recognized for its role in precision medicine, offering hope to patients with BRCA mutations and homologous recombination deficiency (HRD)-positive tumors.
Olaparib, the key component in Lynparza 150 mg, works by inhibiting the enzyme Poly (ADP-ribose) polymerase (PARP), which is essential for cancer cell DNA repair. By blocking this repair mechanism, Lynparza 150 mg causes cancer cells, particularly those with BRCA mutations, to accumulate DNA damage and eventually undergo cell death. This selective targeting of cancer cells makes Lynparza 150 mg a highly effective and less toxic alternative to traditional chemotherapy.
🔬 Key Benefits & Indications of Lynparza 150 mg Olaparib:
- Ovarian Cancer: Lynparza 150 mg is approved as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer, with or without BRCA mutations.
- Breast Cancer: Lynparza 150 mg is a targeted treatment for HER2-negative metastatic breast cancer with BRCA1 or BRCA2 mutations.
- Prostate Cancer: Lynparza 150 mg is indicated for metastatic castration-resistant prostate cancer (mCRPC) with BRCA or other DNA repair mutations.
- Pancreatic Cancer: Lynparza 150 mg is a first-of-its-kind maintenance therapy for BRCA-mutated metastatic pancreatic cancer.
💡 How Lynparza 150 mg Olaparib Works – Mechanism of Action:
- PARP Inhibition: Lynparza 150 mg inhibits the PARP enzyme, blocking the repair of single-strand DNA breaks.
- DNA Damage Accumulation: Cancer cells with BRCA mutations rely heavily on PARP to survive. Lynparza 150 mg prevents repair, causing DNA damage to accumulate.
- Synthetic Lethality: This process results in cancer cell death while sparing normal cells, making Lynparza 150 mg a precision treatment.
💊 Dosage & Administration of Lynparza 150 mg Olaparib:
- Standard Dose: 300 mg (two 150 mg tablets) taken twice daily, with or without food.
- Duration: Treatment continues until disease progression or unacceptable toxicity.
- Important Note: Lynparza tablets and capsules are NOT interchangeable due to differences in dosing and bioavailability.
⚠️ Side Effects of Lynparza 150 mg Olaparib:
- Fatigue and weakness.
- Nausea, vomiting, and decreased appetite.
- Anemia and low blood cell counts.
- Diarrhea or constipation.
- Respiratory issues such as cough or breathlessness.
- Rare but serious side effects: Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and pneumonitis.
🧊 Storage Instructions:
- Store Lynparza 150 mg tablets below 30°C.
- Keep in the original packaging to protect from moisture and light.
- Keep out of reach of children.
🌍 Why Choose Lynparza 150 mg Olaparib by AstraZeneca?
- Pioneering PARP Inhibitor: Lynparza 150 mg was the first FDA-approved PARP inhibitor, revolutionizing cancer treatment.
- Tailored for BRCA Mutations: Designed for patients with BRCA1, BRCA2, and HRD-positive tumors.
- Proven Efficacy: Clinical trials demonstrate significant improvements in progression-free survival and overall quality of life.
- Oral Convenience: Lynparza 150 mg offers a convenient oral alternative to intravenous chemotherapy.
- Global Recognition: Approved by FDA, EMA, and other major health authorities worldwide.
🏆 Clinical Trial Highlights:
- SOLO-1 Trial: Lynparza 150 mg showed a 70% reduction in the risk of disease progression in newly diagnosed BRCA-mutated ovarian cancer patients.
- OlympiA Trial: Lynparza 150 mg reduced the risk of disease recurrence by 42% in BRCA-mutated early breast cancer.
- PROfound Trial: Lynparza 150 mg extended survival in patients with mCRPC and DNA repair gene mutations.
Değerlendirmeler
Henüz değerlendirme yapılmadı.